A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for up to 13 Weeks in Patients With Diabetic Peripheral Neuropathic Pain (DPNP).

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for up to 13 Weeks in Patients With Diabetic Peripheral Neuropathic Pain (DPNP).

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2016

At a glance

  • Drugs Indantadol (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Adverse reactions
  • Acronyms IN-STEP
  • Most Recent Events

    • 22 Jul 2011 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Disappointing preliminary results have been reported in a Vernalis media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top